Skip to Main content Skip to Navigation
Journal articles

L’inflammasome NLRP3 : physiopathologie et application thérapeutique

Abstract : The innate immune system constitutes the first line of host defense against pathogens. "Nonself", such as exogenous particles or pathogens, triggers an inflammatory response. Inflammasomes are molecular platforms activated upon cellular infection or stress that trigger the maturation of proinflammatory cytokines such as IL-1β. Activation of the NLRP3 inflammasome pathway, the most extensively studied, appears to be the corner stone of many inflammatory diseases, including Crohn's disease, rheumatoid arthritis and gout. Cryopyrine-associated periodic syndromes (CAPS) are NLRP3 inflammasome-associated diseases. Canakinumab (Ilaris(®)) is the only drug approved for CAPS treatment in France. Targeted therapy against NLRP3 inflammasome and IL-1β might be the new anti-inflammatory drugs.
Document type :
Journal articles
Complete list of metadatas

Cited literature [81 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01274225
Contributor : Laurent Jonchère <>
Submitted on : Thursday, September 29, 2016 - 11:50:03 AM
Last modification on : Tuesday, March 10, 2020 - 4:28:37 PM

File

Gicquel_NLRP3_Press_Med_2016.p...
Files produced by the author(s)

Identifiers

Citation

Thomas Gicquel, Sacha Robert, Tatiana Victoni, Vincent Lagente. L’inflammasome NLRP3 : physiopathologie et application thérapeutique. La Presse Médicale, Elsevier Masson, 2016, 45 (4, part 1), pp.438-446. ⟨10.1016/j.lpm.2016.01.006⟩. ⟨hal-01274225⟩

Share

Metrics

Record views

432

Files downloads

517